Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

127
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

151
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
151
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

228
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
228
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

78
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
78
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

70
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benefits and challenges of implementing preemptive testing in pharmacogenetics: A case report.

Journal of the American Association of Nurse Practitioners·2026
Same author

From a decentralized clinical trial to a decentralized and clinical-trial-in-a-box platform: Towards patient-centric and equitable trials.

Journal of clinical and translational science·2023
Same author

The use of N-of-1 trials to generate real-world evidence for optimal treatment of individuals and populations.

Journal of clinical and translational science·2023
Same author

Participant and research team perspectives on the conduct of a remote therapeutic COVID-19 clinical trial: A mixed methods approach.

Journal of clinical and translational science·2022
Same author

Systematic Review of Burnout in US Nurses.

The Nursing clinics of North America·2022
Same author

How Do We Reduce Burnout In Nursing?

The Nursing clinics of North America·2022

Related Experiment Video

Updated: Apr 15, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.7K

Using the genotype selection interface: a clinical case study for CYP2C19.

Crystal Dodson1, Dorothy Dulko

  • 1Walden University, Minneapolis, Minnesota.

Journal of the American Association of Nurse Practitioners
|June 10, 2025
PubMed
Summary
This summary is machine-generated.

Pharmacogenetic testing uses genetic information to personalize drug treatments, improving efficacy and reducing adverse drug reactions (ADRs). Enhanced education for clinicians like nurse practitioners (NPs) is crucial for its effective clinical application.

Keywords:
Advanced practice nursingCYP2C19genotype selection interfacemental healthpharmacogenetic testing

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.7K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K

Area of Science:

  • Pharmacogenomics and pharmacology
  • Clinical genetics and personalized medicine

Background:

  • Adverse drug reactions (ADRs) are common, and patient responses to medications vary significantly.
  • Pharmacogenetic testing offers a way to predict drug efficacy and toxicity based on genetic profiles.
  • Limited clinician knowledge of pharmacogenomics necessitates improved educational strategies.

Purpose of the Study:

  • To explore the clinical application of the Genotype Selection Interface for pharmacogenetic testing.
  • To highlight the role of nurse practitioners (NPs) in utilizing pharmacogenetic data for personalized medicine.
  • To discuss the challenges, limitations, and future directions of pharmacogenetic testing in clinical practice.

Main Methods:

  • Application of the Genotype Selection Interface for pharmacogenetic testing.
  • Review of existing literature on pharmacogenomics and clinical practice.
  • Discussion of case studies and clinical scenarios involving pharmacogenetic data.

Main Results:

  • Pharmacogenetic testing can guide medication selection and dosing for improved patient outcomes.
  • Personalized medication regimens based on genetic profiles can reduce the incidence of ADRs.
  • The Genotype Selection Interface provides a framework for integrating pharmacogenetic data into clinical decision-making.

Conclusions:

  • Pharmacogenetic testing is a valuable tool for optimizing drug therapy and enhancing patient safety.
  • Enhanced education and accessible interfaces are needed to facilitate widespread adoption by clinicians, including NPs.
  • Further research is essential to address challenges and expand the future applications of pharmacogenetics in healthcare.